TSXV - Delayed Quote CAD

Thiogenesis Therapeutics, Corp. (TTI.V)

0.5700

-0.0100

(-1.72%)

At close: January 10 at 2:08:32 PM EST

Thiogenesis Announces Presentation on UMDF Webcast Featuring Clinical Trials in Mitochondrial Disease

San Diego, California--(Newsfile Corp. - December 10, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol compounds, including precursors to cysteamine, that have potent antioxidant and anti-inflammatory properties for mitochondrial diseases and related metabolic conditions is pleased to announce that Patrice Rioux, MD, Ph.D., Thiogenesis' Chief Executive Officer, presented an update on the Company's t

Newsfile last month

TTIPF

TTI.V
-1.72%
Thiogenesis Announces DTC Eligibility in the U.S. and Other Updates

San Diego, California--(Newsfile Corp. - November 28, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTC: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol compounds, that includes precursors to cysteamine and that have potent antioxidant and anti-inflammatory properties for the treatment of inherited mitochondrial diseases and metabolic conditions, is pleased to announce that it has attained Depository Trust Company ("DTC") eligibility s

Newsfile last month

TTIPF

TTI.V
-1.72%
Thiogenesis Announces Important Core Patent Allowed in Europe

San Diego, California--(Newsfile Corp. - November 4, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol compounds, including precursors to cysteamine that have potent antioxidant and anti-inflammatory properties for mitochondrial diseases and related metabolic conditions; is pleased to announce that one of its core patents titled, "Methods For The Treatment of Cysteamine Sensitive Disorders," has been

Newsfile 2 months ago

TTI.V
-1.72%
TTIPF
Here's Why We're Watching Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 3 months ago

TTI.V
-1.72%
Thiogenesis Announces Investor Relations Engagement

San Diego, California--(Newsfile Corp. - September 27, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis or the Company) a clinical-stage biotechnology company developing thiol-active compounds that have strong antioxidant and anti-inflammatory properties and that have the potential to treat mitochondrial diseases, including metabolic syndrome, today announced that it has entered into an investor relations agreement (the IR Agreement), effective October 1, 2024, with Triomphe Hold

Newsfile 3 months ago

TTI.V
-1.72%
Thiogenesis Announces Presentation at 3rd Annual Leigh Syndrome Symposium

San Diego, California--(Newsfile Corp. - September 17, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and potent antioxidants targeting unmet pediatric diseases, today announced that Patrice Rioux, M.D., Ph.D., the Company's Chief Executive Officer, has been invited to present this week at the Cure Mito Foundation's "Empower and Inspire: 3rd Annual Leig

Newsfile 3 months ago

TTI.V
-1.72%
Thiogenesis Announces Collaboration and Updates on Pediatric NASH Clinical Program

San Diego, California--(Newsfile Corp. - August 20, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and potent antioxidants targeting unmet pediatric diseases, today announced that it has signed a Collaborative Agreement with the University of California San Diego ("UCSD"). Thiogenesis will work with Jeffrey Schwimmer, M.D., as the Principal Investigator

Newsfile 4 months ago

TTI.V
-1.72%
Thiogenesis Announces Leigh Syndrome Clinical Program

San Diego, California--(Newsfile Corp. - July 18, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and potent antioxidants targeting unmet pediatric diseases, today announced that it has signed a Master Research Agreement with a leading U.S. pediatric hospital. In the agreement, the pediatric hospital will act as the Investigator in assessing Thiogenesis'

Newsfile 5 months ago

TTI.V
-1.72%
Here's Why We're Not Too Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 8 months ago

TTI.V
-1.72%
Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS

San Diego, California--(Newsfile Corp. - March 25, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and that have the potential to treat unmet pediatric diseases, today announced that the European Medicines Agency ("EMA") has accepted its Clinical Trial Application ("CTA") Part I - Scientific and Medicinal Product Documentation, for its lead compound TTI-

Newsfile 9 months ago

TTI.V
-1.72%

Performance Overview

Return	TTI.V	S&P/TSX Composite index
YTD	-5.00%	+0.60%
1-Year	-21.92%	+18.10%
3-Year	+42.50%	+17.47%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Thiogenesis Therapeutics, Corp. (TTI.V)

Thiogenesis Announces Presentation on UMDF Webcast Featuring Clinical Trials in Mitochondrial Disease

Thiogenesis Announces DTC Eligibility in the U.S. and Other Updates

Thiogenesis Announces Important Core Patent Allowed in Europe

Here's Why We're Watching Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Situation

Thiogenesis Announces Investor Relations Engagement

Thiogenesis Announces Presentation at 3rd Annual Leigh Syndrome Symposium

Thiogenesis Announces Collaboration and Updates on Pediatric NASH Clinical Program

Thiogenesis Announces Leigh Syndrome Clinical Program

Here's Why We're Not Too Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Situation

Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS

Performance Overview